MCID: MLG098
MIFTS: 39

Malignant Mixed Mullerian Tumor

Categories: Rare diseases, Cancer diseases

Aliases & Classifications for Malignant Mixed Mullerian Tumor

MalaCards integrated aliases for Malignant Mixed Mullerian Tumor:

Name: Malignant Mixed Mullerian Tumor 53
Carcinosarcoma 53 55 73
Mixed Tumor, Mullerian 53 73
Mixed Tumor, Not Otherwise Specified 73
Malignant Mixed Mesodermal Tumor 73
Mixed Mullerian Tumor 53
Mixed Tumor Mullerian 55
Mmmt 53

Classifications:



External Ids:

Summaries for Malignant Mixed Mullerian Tumor

NIH Rare Diseases : 53 A malignant mixed müllerian tumor (MMMT), also called a carcinosarcoma, is a type of cancer that contains two types of cancer cells - carcinoma and sarcoma cells. These tumors usually develop in tissues of the female genital tract and are associated with a poor outcome. The majority of these tumors arise in the uterus, though they can also occur in the ovaries, fallopian tubes, and cervix. Very rarely, MMMTs can develop in the female peritoneum (lining of the abdominal wall).

MalaCards based summary : Malignant Mixed Mullerian Tumor, also known as carcinosarcoma, is related to papillary serous adenocarcinoma and leiomyoma. An important gene associated with Malignant Mixed Mullerian Tumor is VIM (Vimentin), and among its related pathways/superpathways are Cytoskeletal Signaling and Cytoskeleton remodeling Neurofilaments. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include uterus, ovary and cervix.

Wikipedia : 76 A malignant mixed Müllerian tumor, also known as malignant mixed mesodermal tumor, MMMT and... more...

Related Diseases for Malignant Mixed Mullerian Tumor

Diseases related to Malignant Mixed Mullerian Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 215)
# Related Disease Score Top Affiliating Genes
1 papillary serous adenocarcinoma 30.1 KRT7 PGR
2 leiomyoma 28.8 KIT PGR VIM
3 ovarian carcinosarcoma 11.9
4 vaginal carcinosarcoma 11.2
5 fallopian tube carcinosarcoma 11.2
6 cervical carcinosarcoma 11.2
7 malignant peritoneal mesothelioma 10.4 MUC1 VIM
8 papillary tumor of the pineal region 10.4 MUC1 VIM
9 adenoid squamous cell carcinoma 10.4 KRT7 VIM
10 ossifying fibromyxoid tumor 10.4 MUC1 VIM
11 fibrous meningioma 10.4 MUC1 VIM
12 chordoid meningioma 10.4 MUC1 VIM
13 papillary adenoma 10.4 KRT7 VIM
14 syringocystadenoma papilliferum 10.4 MUC1 VIM
15 eccrine porocarcinoma 10.4 MUC1 VIM
16 biphasic synovial sarcoma 10.4 MUC1 VIM
17 adenofibroma 10.4 MUC1 VIM
18 myxopapillary ependymoma 10.4 MUC1 VIM
19 syringoma 10.4 MUC1 VIM
20 medulloepithelioma 10.4 KRT7 VIM
21 metanephric adenoma 10.4 KRT7 VIM
22 pleomorphic liposarcoma 10.4 MUC1 VIM
23 adenomatoid tumor 10.4 KRT7 VIM
24 desmoplastic small round cell tumor 10.4 MUC1 VIM
25 anaplastic ependymoma 10.4 MUC1 VIM
26 reticulum cell sarcoma 10.4 MUC1 VIM
27 sertoli cell tumor 10.4 MUC1 VIM
28 mesenchymal chondrosarcoma 10.4 MUC1 VIM
29 extraskeletal ewing sarcoma 10.4 MUC1 VIM
30 endocervical adenocarcinoma 10.4 KRT7 VIM
31 solid adenocarcinoma with mucin production 10.4 KRT7 MUC1
32 chondroid chordoma 10.4 MUC1 VIM
33 endodermal sinus tumor 10.3 KRT7 VIM
34 bile duct mucoepidermoid carcinoma 10.3 KRT7 MUC1
35 middle ear adenoma 10.3 KRT7 MUC1
36 dendritic cell tumor 10.3 MUC1 VIM
37 mucinous bronchioloalveolar adenocarcinoma 10.3 KRT7 MUC1
38 rhabdoid cancer 10.3 MUC1 VIM
39 bile duct cystadenocarcinoma 10.3 KRT7 MUC1
40 cerebral primitive neuroectodermal tumor 10.3 MUC1 VIM
41 hemangiopericytoma, malignant 10.3 MUC1 VIM
42 nephrogenic adenoma 10.3 KRT7 MUC1
43 adenomyoma 10.3 KRT7 MUC1
44 granulosa cell tumor of the ovary 10.3 KRT7 VIM
45 hidradenocarcinoma 10.3 KRT7 VIM
46 mucinous ovarian cystadenoma 10.3 KRT7 MUC1
47 lymphangiomatosis 10.3 PGR VIM
48 well-differentiated liposarcoma 10.3 KRT7 MUC1
49 epulis 10.3 PGR VIM
50 paget disease, extramammary 10.3 KRT7 MUC1

Graphical network of the top 20 diseases related to Malignant Mixed Mullerian Tumor:



Diseases related to Malignant Mixed Mullerian Tumor

Symptoms & Phenotypes for Malignant Mixed Mullerian Tumor

Drugs & Therapeutics for Malignant Mixed Mullerian Tumor

Drugs for Malignant Mixed Mullerian Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
3
Lenograstim Approved, Investigational Phase 3,Phase 1 135968-09-1
4
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
5
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
6
Mechlorethamine Approved, Investigational Phase 3,Phase 2 51-75-2 4033
7
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
8
Mesna Approved, Investigational Phase 3,Phase 2 3375-50-6 598
9
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
10
Cyproheptadine Approved Phase 3 129-03-3 2913
11
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
12
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
13 Alkylating Agents Phase 3,Phase 2
14 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1,Not Applicable
15 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
16 Antineoplastic Agents, Alkylating Phase 3,Phase 2
17 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
18
Isophosphamide mustard Phase 3,Phase 2 0
19 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
20 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
21 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
22 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
23 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
24
Histamine Phosphate Phase 3 51-74-1 65513
25 Serotonin Agents Phase 3
26 Serotonin Antagonists Phase 3
27 Gastrointestinal Agents Phase 3
28 Neurotransmitter Agents Phase 3
29 Histamine Antagonists Phase 3
30 Histamine H1 Antagonists Phase 3
31 Dermatologic Agents Phase 3
32 Anti-Allergic Agents Phase 3
33 Antipruritics Phase 3
34
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
35
Gemcitabine Approved Phase 2 95058-81-4 60750
36
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
37
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
38
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
39
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
40
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
41
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 43805 6857599
42
Everolimus Approved Phase 2 159351-69-6 6442177
43
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
44
Docetaxel Approved, Investigational Phase 2,Phase 1 114977-28-5 148124
45
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
46
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
47
Metformin Approved Phase 2 657-24-9 14219 4091
48
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
49
Levonorgestrel Approved, Investigational Phase 2 797-63-7, 17489-40-6 13109
50
nivolumab Approved Phase 2 946414-94-4

Interventional clinical trials:

(show top 50) (show all 77)
# Name Status NCT ID Phase Drugs
1 Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus Completed NCT00003128 Phase 3 ifosfamide;paclitaxel
2 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus Completed NCT00002546 Phase 3 cisplatin;ifosfamide
3 Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus Completed NCT00002459 Phase 3
4 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
5 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
6 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
7 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Active, not recruiting NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
8 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
9 Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble - Unknown status NCT02203760 Phase 2 Pazopanib plus Gemcitabine;Pazopanib
10 Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Unknown status NCT00838656 Phase 2 carboplatin;gemcitabine hydrochloride;paclitaxel
11 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
12 Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus Completed NCT00502203 Phase 2 Carboplatin;Paclitaxel
13 Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Completed NCT00687687 Phase 2 paclitaxel;carboplatin;BSI-201 (Iniparib)
14 Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus Completed NCT00476086 Phase 2 Gemcitabine;Oxaliplatin
15 Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2 Thalidomide
16 Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors Completed NCT00520013 Phase 2 bevacizumab;erlotinib;paclitaxel;carboplatin
17 Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01247571 Phase 2 Pazopanib Hydrochloride
18 Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01168232 Phase 2 Ixabepilone
19 Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00114218 Phase 2 Gemcitabine Hydrochloride;Docetaxel
20 Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00075400 Phase 2 imatinib mesylate
21 A Phase II Trial of Adjuvant Radiation Therapy With Ifosfamide in Patients With MMT of the Uterus Completed NCT00231842 Phase 2 Ifosfamide
22 Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer Completed NCT00238121 Phase 2 sorafenib tosylate
23 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2 PegLiposomal Doxorubicin;Carboplatin
24 Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer Completed NCT00112489 Phase 2 carboplatin;paclitaxel
25 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed NCT00390234 Phase 2 ziv-aflibercept
26 Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer Completed NCT00511992 Phase 2 Avastin;Paclitaxel;Cisplatin
27 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2 Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
28 Carboplatin Taxol Avastin in Ovarian Cancer (OVCA) Completed NCT00129727 Phase 2 Paclitaxel;Carboplatin;Bevacizumab
29 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
30 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
31 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
32 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
33 Chemotherapy in Treating Patients With Sarcoma of the Uterus Completed NCT00005643 Phase 2 pegylated liposomal doxorubicin hydrochloride
34 Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract Completed NCT00003334 Phase 2 paclitaxel;pegylated liposomal doxorubicin hydrochloride
35 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
36 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
37 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
38 Thalidomide in Treating Patients With Gynecologic Sarcomas Completed NCT00006005 Phase 2 thalidomide
39 Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer Completed NCT00032162 Phase 1, Phase 2 carboplatin;pegylated liposomal doxorubicin hydrochloride
40 Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer Completed NCT00392769 Phase 2 Cetuximab
41 A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer Recruiting NCT03015129 Phase 2 Durvalumab;Tremelimumab
42 Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel? Recruiting NCT03570437 Phase 2 Paclitaxel;Cediranib;Olaparib
43 Vorinostat (SAHA) in Uterine Sarcoma Recruiting NCT03509207 Phase 2 Vorinostat Oral Capsule
44 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
45 A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers Recruiting NCT02923934 Phase 2 Ipilimumab;Nivolumab
46 Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Recruiting NCT02874430 Phase 2 Metformin Hydrochloride;Doxycycline
47 Phase II Study of Intrauterine Device (IUD) Alone or in Combination With Everolimus in Endometrial Cancer Recruiting NCT02397083 Phase 2 Everolimus
48 A Study of Nivolumab in Selected Uterine Cancer Patients Recruiting NCT03241745 Phase 2 Nivolumab
49 Fludeoxyglucose F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Active, not recruiting NCT00416455 Phase 1, Phase 2 ferumoxtran-10
50 Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT00478426 Phase 2 Sunitinib Malate

Search NIH Clinical Center for Malignant Mixed Mullerian Tumor

Genetic Tests for Malignant Mixed Mullerian Tumor

Anatomical Context for Malignant Mixed Mullerian Tumor

MalaCards organs/tissues related to Malignant Mixed Mullerian Tumor:

41
Uterus, Ovary, Cervix, Bone, Smooth Muscle, Skeletal Muscle, Prostate

Publications for Malignant Mixed Mullerian Tumor

Articles related to Malignant Mixed Mullerian Tumor:

(show top 50) (show all 60)
# Title Authors Year
1
Gas Gangrene of Malignant Mixed Mullerian Tumor of Ovary Caused by Clostridium perfringens. ( 29685470 )
2018
2
Malignant mixed mullerian tumor of ovary-scrape cytology: Findings with review of literature. ( 28469326 )
2017
3
Extremely Locally Advanced Ovarian Malignant Mixed Mullerian Tumor in 37-Years-Old Female. ( 28593890 )
2017
4
Serous Carcinoma component championed by Heparin Binding-EGF Like Growth Factor (HB-EGF) Predisposing to Metastasis and Recurrence in Stage I Uterine Malignant Mixed Mullerian Tumor. ( 26980026 )
2016
5
Extragenital malignant mixed Mullerian tumor in the incisional hernia - primary carcinosarcoma in the abdominal wall: case report. ( 26012132 )
2015
6
Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor. ( 26711836 )
2015
7
Serous Ovarian Carcinoma Recurring as Malignant Mixed Mullerian Tumor. ( 26713165 )
2015
8
Endometrioid carcinoma infiltrating atypical leiomyoma: a mimicker of malignant mixed Mullerian tumor. ( 24943777 )
2014
9
Prolonged survival of a patient with pelvic recurrence of ovarian malignant mixed mullerian tumor after chemoradiotherapy. ( 25593719 )
2014
10
F-18 fluorodeoxyglucose positron emission tomography/computed tomography in a rare case of recurrent malignant mixed mullerian tumor. ( 25191116 )
2014
11
Malignant mixed mullerian tumor of the ovary. ( 25404814 )
2014
12
ANNA-1 (anti-Hu) associated sensory neuronopathy with malignant mixed mullerian tumor. ( 23536385 )
2013
13
Malignant mixed mullerian tumor of endometrium coexisting with bilateral papillary serous adenocarcinoma of fallopian tube: a rare case report. ( 24293882 )
2012
14
Malignant mixed mullerian tumor: an immunohistochemical study. ( 22848863 )
2012
15
Malignant mixed Mullerian tumor of broad ligament with synchronous ovarian and endometrial carcinoma: a rare association. ( 21546752 )
2011
16
Ovarian malignant mixed mullerian tumor with primitive neuroectodermal differentiation: case report with review of the literature. ( 20950943 )
2011
17
Uncommon manifestations of Endocervical Malignant Mixed Mullerian Tumor with Incidental Bilateral Fallopian Tube Carcinoma. ( 21701666 )
2011
18
Malignant mixed Mullerian tumor of the ovary with two cases and review of the literature. ( 21298439 )
2011
19
Malignant mixed mullerian tumor of the cervix including components of a rhabdomyosarcoma: case report and literature review. ( 20882897 )
2010
20
Bilateral ovarian malignant mixed Mullerian tumor in a dog. ( 19176505 )
2009
21
Extra genital heterologous malignant mixed mullerian tumor of primary peritoneal origin. ( 19136793 )
2009
22
Biopsy-proven cerebellar metastasis from a malignant mixed mullerian tumor (MMMT) of the uterus: case report. ( 19480254 )
2009
23
Homologous type of malignant mixed Mullerian tumor of the uterus presenting as a cervical mass. ( 19837648 )
2009
24
Intracardiac metastasis of a Malignant Mixed Mullerian tumor (MMMT): progressive dyspnoea due to obstruction of the left atrium and the left ventricle without left ventricular dysfunction or primary lung disease. ( 19652943 )
2009
25
Comparative analysis of P16 and P53 expression in uterine malignant mixed mullerian tumors. ( 19851197 )
2009
26
Malignant mixed mullerian tumor of the urinary bladder in a 73 year old woman. ( 18559304 )
2008
27
Primary malignant mixed mullerian tumor of the uterus: findings on sonography, CT, and gadolinium-enhanced MRI. ( 18562759 )
2008
28
CT imaging of a primary malignant mixed mullerian tumor arising from the peritoneum. ( 18760728 )
2008
29
Malignant mixed mullerian tumor of the vagina: case report with review of the literature, immunohistochemical study, and evaluation for human papilloma virus. ( 17640554 )
2007
30
Pancreatic metastasis of an ovarian malignant mixed Mullerian tumor identified by EUS-guided fine needle aspiration and Trucut needle biopsy. ( 16407622 )
2006
31
Malignant mixed mullerian tumor in a rabbit (Oryctolagus cuniculus): case report with immunohistochemistry. ( 16847001 )
2006
32
Paraneoplastic subacute sensory neuronopathy secondary to a malignant mixed mullerian tumor. ( 16449165 )
2006
33
Diagnostic dilemma in a case of malignant mixed mullerian tumor of the cervix. ( 16813659 )
2006
34
Primary malignant mixed Mullerian tumor arising in the rectosigmoid. ( 16612719 )
2006
35
Malignant mixed mullerian tumor (MMMT) of the cervix. ( 15863143 )
2005
36
Primary malignant mixed mullerian tumor of the vagina immunohistochemically confirmed. ( 14735374 )
2005
37
Primary peritoneal carcinosarcoma (malignant mixed mullerian tumor): Report of a case with five-year disease free survival after surgery and chemoradiation and a review of literature. ( 16227168 )
2005
38
Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene. ( 15863610 )
2005
39
Malignant mixed Mullerian tumor of the fimbriated end of the fallopian tube: origin as an intraepithelial carcinoma. ( 15790462 )
2005
40
Presentation with superior vena cava syndrome secondary to solitary lung metastasis mimicking primary lung cancer following resection of a uterine malignant mixed mullerian tumor: brief case report. ( 15653218 )
2005
41
Comment on "Malignant mixed Mullerian tumor of the ovary: an argument for BRCA3 or a coincidental cluster of unconnected cancer". ( 15582005 )
2004
42
Malignant mixed Mullerian tumor of the ovary growing into an inguinal hernia sac: report of a case. ( 14513334 )
2003
43
Malignant mixed Mullerian tumor of the uterine corpus with alpha-fetoprotein-producing hepatoid adenocarcinoma component. ( 14599882 )
2003
44
Malignant mixed mullerian tumor of the ovary and bilateral breast cancer: an argument for BRCA3, or a coincidental cluster of unconnected cancers? ( 14599878 )
2003
45
Malignant mixed Mullerian tumor of the uterine cervix with neuroendocrine differentiation. ( 11975686 )
2002
46
Malignant mixed mullerian tumor of the ovary: report of four cases. ( 11321500 )
2001
47
Good response of malignant mixed mullerian tumor of the ovary to paclitaxel and cisplatin chemotherapy. ( 10609493 )
1999
48
Malignant mixed mesodermal tumor arising in a benign cystic teratoma. ( 10391531 )
1999
49
Malignant mixed mullerian tumor of the female peritoneum: treatment and outcome of three cases. ( 9190987 )
1997
50
Malignant Mixed Mullerian Tumor of the Extra-genital Coelomic Epithelium: Report of Two Cases. ( 11173640 )
1997

Variations for Malignant Mixed Mullerian Tumor

Cosmic variations for Malignant Mixed Mullerian Tumor:

9
(show top 50) (show all 122)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM10663 TP53 ovary,NS,carcinoma,adenocarcinoma c.916C>T p.R306* 17:7673704-7673704 4
2 COSM11066 TP53 ovary,NS,carcinoma,adenocarcinoma c.578A>T p.H193L 17:7674953-7674953 4
3 COSM10738 TP53 ovary,NS,carcinoma,adenocarcinoma c.542G>A p.R181H 17:7675070-7675070 4
4 COSM11148 TP53 ovary,NS,carcinoma,adenocarcinoma c.476C>T p.A159V 17:7675136-7675136 4
5 COSM11582 TP53 ovary,NS,carcinoma,adenocarcinoma c.395A>G p.K132R 17:7675217-7675217 4
6 COSM6904336 TNFAIP3 ovary,NS,carcinoma,adenocarcinoma c.940G>A p.V314I 6:137877210-137877210 4
7 COSM14135 SMAD4 ovary,NS,carcinoma,adenocarcinoma c.1051G>C p.D351H 18:51065518-51065518 4
8 COSM6904335 SMAD2 ovary,NS,carcinoma,adenocarcinoma c.785-1G>C p.? 18:47848688-47848688 4
9 COSM6904334 RET ovary,NS,carcinoma,adenocarcinoma c.3253A>G p.T1085A 10:43128177-43128177 4
10 COSM6904339 PTCH1 ovary,NS,carcinoma,adenocarcinoma c.3074G>A p.R1025H 9:95458107-95458107 4
11 COSM760 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.1624G>A p.E542K 3:179218294-179218294 4
12 COSM770 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.2725T>C p.F909L 3:179230062-179230062 4
13 COSM21446 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.3012G>T p.M1004I 3:179234169-179234169 4
14 COSM746 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.263G>A p.R88Q 3:179199088-179199088 4
15 COSM94978 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.1034A>T p.N345I 3:179203764-179203764 4
16 COSM766 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.1636C>A p.Q546K 3:179218306-179218306 4
17 COSM580 NRAS ovary,NS,carcinoma,adenocarcinoma c.181C>A p.Q61K 1:114713909-114713909 4
18 COSM564 NRAS ovary,NS,carcinoma,adenocarcinoma c.35G>A p.G12D 1:114716126-114716126 4
19 COSM522 KRAS ovary,NS,carcinoma,adenocarcinoma c.35G>C p.G12A 12:25245350-25245350 4
20 COSM14065 ERBB2 ovary,NS,carcinoma,adenocarcinoma c.2524G>A p.V842I 17:39725079-39725079 4
21 COSM22992 EGFR ovary,NS,carcinoma,adenocarcinoma c.2161G>A p.G721S 7:55174020-55174020 4
22 COSM53264 EGFR ovary,NS,carcinoma,adenocarcinoma c.2174C>T p.T725M 7:55174033-55174033 4
23 COSM53230 EGFR ovary,NS,carcinoma,adenocarcinoma c.2597A>G p.E866G 7:55191846-55191846 4
24 COSM28511 EGFR ovary,NS,carcinoma,adenocarcinoma c.2108T>C p.L703P 7:55173967-55173967 4
25 COSM53225 EGFR ovary,NS,carcinoma,adenocarcinoma c.2112G>A p.L704L 7:55173971-55173971 4
26 COSM53232 EGFR ovary,NS,carcinoma,adenocarcinoma c.2122A>G p.K708E 7:55173981-55173981 4
27 COSM53266 EGFR ovary,NS,carcinoma,adenocarcinoma c.2165C>T p.A722V 7:55174024-55174024 4
28 COSM53224 EGFR ovary,NS,carcinoma,adenocarcinoma c.2173A>G p.T725A 7:55174032-55174032 4
29 COSM53213 EGFR ovary,NS,carcinoma,adenocarcinoma c.2604A>T p.E868D 7:55191853-55191853 4
30 COSM53229 EGFR ovary,NS,carcinoma,adenocarcinoma c.2232C>A p.I744I 7:55174769-55174769 4
31 COSM53231 EGFR ovary,NS,carcinoma,adenocarcinoma c.2559C>T p.I853I 7:55191808-55191808 4
32 COSM12373 EGFR ovary,NS,carcinoma,adenocarcinoma c.2159C>T p.S720F 7:55174018-55174018 4
33 COSM53265 EGFR ovary,NS,carcinoma,adenocarcinoma c.2556G>T p.K852N 7:55191805-55191805 4
34 COSM53235 EGFR ovary,NS,carcinoma,adenocarcinoma c.2481C>T p.Y827Y 7:55191730-55191730 4
35 COSM53226 EGFR ovary,NS,carcinoma,adenocarcinoma c.2099A>G p.N700S 7:55173958-55173958 4
36 COSM28286 EGFR ovary,NS,carcinoma,adenocarcinoma c.2494C>T p.R832C 7:55191743-55191743 4
37 COSM53228 EGFR ovary,NS,carcinoma,adenocarcinoma c.2123A>G p.K708R 7:55173982-55173982 4
38 COSM53227 EGFR ovary,NS,carcinoma,adenocarcinoma c.2506C>A p.R836S 7:55191755-55191755 4
39 COSM6224 EGFR ovary,NS,carcinoma,adenocarcinoma c.2573T>G p.L858R 7:55191822-55191822 4
40 COSM22499 ATM ovary,NS,carcinoma,adenocarcinoma c.1810C>T p.P604S 11:108252824-108252824 4
41 COSM6904304 AR ovary,NS,carcinoma,adenocarcinoma c.2179C>T p.R727C 23:67717483-67717483 4
42 COSM159008 AKT1 ovary,NS,carcinoma,adenocarcinoma c.235C>A p.Q79K 14:104776711-104776711 4
43 COSM1235014 U2AF1 cervix,NS,carcinoma,adenocarcinoma c.467G>A p.R156H 21:43094670-43094670 3
44 COSM10648 TP53 cervix,NS,carcinoma,adenocarcinoma c.524G>A p.R175H 17:7675088-7675088 3
45 COSM44399 TP53 cervix,NS,carcinoma,adenocarcinoma c.677G>T p.G226V 17:7674286-7674286 3
46 COSM10941 TP53 cervix,NS,carcinoma,adenocarcinoma c.730G>A p.G244S 17:7674233-7674233 3
47 COSM10725 TP53 cervix,NS,carcinoma,adenocarcinoma c.701A>G p.Y234C 17:7674262-7674262 3
48 COSM10662 TP53 cervix,NS,carcinoma,adenocarcinoma c.743G>A p.R248Q 17:7674220-7674220 3
49 COSM11333 TP53 cervix,NS,carcinoma,adenocarcinoma c.499C>T p.Q167* 17:7675113-7675113 3
50 COSM10656 TP53 cervix,NS,carcinoma,adenocarcinoma c.742C>T p.R248W 17:7674221-7674221 3

Expression for Malignant Mixed Mullerian Tumor

Search GEO for disease gene expression data for Malignant Mixed Mullerian Tumor.

Pathways for Malignant Mixed Mullerian Tumor

Pathways related to Malignant Mixed Mullerian Tumor according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.29 KRT7 MUC1 VIM
2
Show member pathways
10.99 KRT7 VIM

GO Terms for Malignant Mixed Mullerian Tumor

Biological processes related to Malignant Mixed Mullerian Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 8.8 KIT MUC1 VIM

Sources for Malignant Mixed Mullerian Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....